Aug 25 (Reuters) - The National Institutes of Health has initiated a late-stage study to test plasma-derived COVID-19 therapies including Emergent BioSolutions Inc's candidate as a potential outpatient treatment for those at high risk of progression to severe disease, the drug developer said on Wednesday. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)